<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20001">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893411</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ60201_3070_1</org_study_id>
    <secondary_id>2012-005054-30</secondary_id>
    <nct_id>NCT01893411</nct_id>
  </id_info>
  <brief_title>Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy</brief_title>
  <official_title>Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Estonia: The State Agency of Medicine</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether injections of Botulinum toxin type A into
      muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with
      increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline (Day 1) in the Ashworth Scale (AS) score of plantar flexors at Day 29 of the 1st injection cycle.</measure>
    <time_frame>Baseline to week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The AS is a well known and commonly used scale in clinical trials with spasticity. In spastic muscles the resistance to passive movement is assessed. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary variable: Investigator's Global Impression of Change of Plantar Flexor Spasticity Scale (GICS-PF) at Day 29 of the 1st injection cycle.</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The GICS-PF scale is a 7-Point Likert Scale for the assessment of the functional change due to treatment of plantar flexor spasticity only. Ranges from +3 (very much improved function) to -3 (very much worse function).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the AS score of plantar flexors of the other treated body side at Day 29 of the 1st and 2nd injection cycle.</measure>
    <time_frame>Baseline up to week 16-40</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the AS score of plantar flexors at Day 29 of the 2nd injection cycle.</measure>
    <time_frame>Week 12-36 to week 16-40</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in AS score of plantar flexors at Day 57 and Day 85 of the 1st and of the 2nd injection cycle.</measure>
    <time_frame>Baseline up to week 24-48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in AS score of knee flexors or thigh adductors at Day 29 of the 1st and of the 2nd injection cycle.</measure>
    <time_frame>Baseline up to week 16-40</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in modified Tardieu Scale [MTS] of plantar flexors at Day 29, Day 57, and Day 85 of the 1st and of the 2nd injection cycle.</measure>
    <time_frame>Baseline up to week 24-48</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Modified Tardieu Scale (MTS) assesses spastic muscle tone by subtraction of two angles measured at different conditions of passive muscle stretch. R2 is the angle of passive range of motion with a passive movement at slow speed. R1 is the angle where a &quot;catch-and-release&quot; or clonus can be triggered at the fastest possible speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's, Child's/Adolescent's, and Parent's/Caregiver's Global Impression of Change Scale [GICS] at Day 29 of the 1st and 2nd injection cycle.</measure>
    <time_frame>Week 12 up to week 16-40</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Global Impression of Change Scales (GICS) are global outcomes to assess the impression of change due to treatment. GICS will be assessed by the investigator, by the subject (if feasible) and by parents'/caregiver (if applicable). GICS are 7-Point Likert Scales ranging from +3 (very much improved function) to -3 (very much worse function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Impression of Change of GICS-PF at Day 29 of the 1st and 2nd injection cycle.</measure>
    <time_frame>Week 12 up to week 16-40</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Gross Motor Function Measure [GMFM]-66 score at the End of 1st Cycle and at the End of Study Visit.</measure>
    <time_frame>Baseline up to week 28-52</time_frame>
    <safety_issue>No</safety_issue>
    <description>The GMFM-66 is a standardized observational 66-item instrument designed and validated to measure change in gross motor function over time in subjects with cerebral palsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores of pain intensity (from subjects) and pain frequency (from parent/caregiver) to all post baseline visits of the 1st and of the 2nd injection cycle.</measure>
    <time_frame>Baseline up to week 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>The QPS is a patient-reported outcome for children and adolescents (2-17 years) with cerebral palsy on spasticity-related pain. Pain intensity (from subjects) and pain frequency (from parent/caregiver) to be assessed with 'Questionnaire on Pain caused by Spasticity [QPS]'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reinjection for each of the three dose groups for the 1st and 2nd injection cycle</measure>
    <time_frame>Baseline up to week 24-72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lower Limb Spasticity Due to Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>16 Units per kg body weight incobotulinumtoxinA (Xeomin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 Units per kg body weight incobotulinumtoxinA (Xeomin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Units per kg body weight incobotulinumtoxinA (Xeomin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (16 Units per kg body weight)</intervention_name>
    <description>Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.</description>
    <arm_group_label>16 Units per kg body weight incobotulinumtoxinA (Xeomin)</arm_group_label>
    <other_name>Xeomin</other_name>
    <other_name>NT 201</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (12 Units per kg body weight)</intervention_name>
    <description>Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.</description>
    <arm_group_label>12 Units per kg body weight incobotulinumtoxinA (Xeomin)</arm_group_label>
    <other_name>Xeomin</other_name>
    <other_name>NT 201</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (4 Units per kg body weight)</intervention_name>
    <description>Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.</description>
    <arm_group_label>4 Units per kg body weight incobotulinumtoxinA (Xeomin)</arm_group_label>
    <other_name>Xeomin</other_name>
    <other_name>NT 201</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male subject of 2 to 17 years of age (inclusive).

          -  Uni- or bilateral cerebral palsy with clinical need for uni- or bilateral LL
             injections with BoNT for the treatment of spasticity.

          -  Ashworth Scale [AS] score ≥2 in plantar flexors (at least unilaterally).

          -  Clinical need for a total dose of 16 U/kg BW NT 201 (maximum of 400 U) for the
             treatment of LL spasticity according to the clinical judgment of the investigator.

        Exclusion Criteria:

          -  Fixed contracture defined as severe restriction of the range of joint movement on
             passive stretch or predominant forms of muscle hypertonia other than spasticity
             (e.g., dystonia) in the target limb(s).

          -  Surgery on pes equinus on side(s) intended to be treated with BoNT injections in this
             study within 12 months prior to Screening Visit (V1), in the screening period or
             planned for the time of participation in this study.

          -  Hip flexion requiring BoNT injection.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manager Public Disclosure</last_name>
    <email>clinicaltrials@merz.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Merz Investigational Site #043039</name>
      <address>
        <city>Bregenz</city>
        <zip>6900</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #043037</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #043036</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #043038</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #420029</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #420028</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #420048</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #372001</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #372002</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049328</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049330</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049329</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049327</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049326</name>
      <address>
        <city>Vogtareuth</city>
        <zip>83569</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #082019</name>
      <address>
        <city>Goyang</city>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #082021</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #082018</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #082020</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048063</name>
      <address>
        <city>Gdansk</city>
        <zip>80-389</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048059</name>
      <address>
        <city>Kraków</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048061</name>
      <address>
        <city>Warsaw</city>
        <zip>02-315</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #040001</name>
      <address>
        <city>Bucharest</city>
        <zip>041914</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #040003</name>
      <address>
        <city>Bucharest</city>
        <zip>041408</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #040002</name>
      <address>
        <city>Iasi</city>
        <zip>700309</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #421003</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97409</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #421002</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97404</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #421005</name>
      <address>
        <city>Bratislava</city>
        <zip>83340</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #421006</name>
      <address>
        <city>Krompachy</city>
        <zip>05342</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #421004</name>
      <address>
        <city>Levoca</city>
        <zip>05401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #090004</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #090005</name>
      <address>
        <city>Elazig</city>
        <zip>23119</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #090002</name>
      <address>
        <city>Izmit</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #380001</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #380005</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #380002</name>
      <address>
        <city>Kiev</city>
        <zip>04209</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #380003</name>
      <address>
        <city>Odessa</city>
        <zip>65011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Paralysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
